June 19, 2009 – Mayer Brown, a leading global law firm, announced that its practices are ranked in 21 categories in the 2009 edition of Legal 500: Europe, Middle East & Africa.
The implementation of REACH is challenging to manufacturers and importers preparing for registration, especially for non-EUbased manufacturers having to appoint an Only Representative (OR). An often overlooked but crucial aspect of OR operation is their taxation.
Regulation (EC) No 1272/2008 on the Classification, Labelling and Packaging (CLP) of chemical substances and mixtures, which implements the UN Globally Harmonised System (GHS) at EU level, entered into force on 20 January 2009.
REACH has been in force since 1 June 2007. However, as REACH enforcement has been entrusted to Member States’ authorities and they were only obliged to lay down provisions on penalties for REACH infringement by 1 December 2008, it is only recently that this has become an important issue.
This month, we examine the organisational and data sharing issues that need to be considered in elaborating consortium agreements. Both of these issues have a direct impact on cost – often the most critical factor in consortium discussions.
In a move that may revolutionize the way dangerous chemicals and processes are regulated in the United States, California Governor Arnold Schwarzenegger has signed into law AB 1879 (Feuer) and SB 509 (Simitian), creating the nation’s first Green Chemistry program. The new laws codify two of the Green Chemistry initiative’s goals: raising public awareness about the hazards of “chemicals of concern,” and finding alternatives that are less threatening to the environment and public health.
The entry into force of the REACH Regulation in 2007 created a new benchmark that other countries have felt compelled to consider, whether in order to improve their own national system, to prevent REACH from becoming the new de facto world standard on chemicals management, or more straightforwardly to facilitate exports of domestic products into the EU market and to create a level playing field for EU imports. But how to respond? Igor Danilov of Mayer Brown explores the question.
As REACH consortia become established and registration compliance strategies are agreed upon, companies should ensure that they also achieve competition law compliance from the outset.
16 June 2006 - The European Union has passed the draft Regulation on Registration, Evaluation and Authorisation of Chemicals ("REACH") in a first stage of the European legislative process. Some conclusion can be drawn at this moment: (1) The REACH legislation will substantially influence the way companies will have to do business in Europe; (2) there are serious implications for confidential and proprietary data that are used to produce and test chemicals; and (3) there is still time to obtain changes or influence the drafting of implementing rules that can mitigate the confidentiality and proprietary data problems.
3 November 2005 - The European Union is moving forward with sweeping new legislation that will affect the sale of chemicals and products
that contain chemicals in Europe, as early as 2007. The proposed legislation, called REACH ("Registration, Evaluation and Authorisation of CHemicals") will, with some exceptions, require all chemicals and all downstream uses of chemicals to be registered both with a new European Chemicals Agency as well as with individual member countries of the European Union.
28 February 2003 - "Forget Dolly the sheep (God rest her woolly soul), lawyers at Mayer, Brown, Rowe & Maw have been busy on behalf of the biosciences industry creating new legal life in the form of the Biosciences Federation."
August 2002 - Drug advertising is a legal minefield for companies that make prescription products. Unlike non-prescription medicines such as cold and flu remedies, which are freely advertised in all media, prescription-only drugs are monitored by the government and advertising is strictly banned.
May 2002 - The biotech industry has come a long way from the days when it was viewed by most people as an offshoot of the pharmaceuticals industry. These days, however, with biotech firms involved in anything from contact lens development to genetic research, biotechs are certainly flavour of the month in investor circles. Chris Sims reports.
Mayer Brown is a global legal services organization comprising legal
practices that are separate entities (the "Mayer Brown Practices"). The
Mayer Brown Practices are: Mayer Brown LLP, a limited liability
partnership established in the United States; Mayer Brown International
LLP, a limited liability partnership incorporated in England and Wales;
and JSM, a Hong Kong partnership, and its associated entities in Asia. The
Mayer Brown Practices are known as Mayer Brown JSM in Asia. "Mayer Brown"
and the "Mayer Brown" logo are the trademarks of the individual Mayer
Brown Practices in their respective jurisdictions.
